For the quarter ending 2026-03-31, COYA has $53,271,099 in assets. $4,300,739 in debts. $50,724,643 in cash and cash equivalents.
| Balance Sheets | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Cash and cash equivalents | 50,724,643 | 46,822,786 | 28,129,866 | 29,757,328 |
| Prepaids and other current assets | 2,538,036 | 3,116,232 | 3,894,944 | 3,670,319 |
| Total current assets | 53,262,679 | 49,939,018 | 32,024,810 | 33,427,647 |
| Fixed assets, net | 8,420 | 11,227 | 18,068 | 24,908 |
| Total assets | 53,271,099 | 49,950,245 | 32,042,878 | 33,452,555 |
| Accounts payable | 948,192 | 1,061,122 | 1,111,702 | 931,344 |
| Accrued expenses | 1,355,714 | 3,612,913 | 1,638,706 | 2,838,685 |
| Deferred collaboration revenue | 1,242,635 | 1,197,856 | 916,712 | 731,075 |
| Total current liabilities | 3,546,541 | 5,871,891 | 3,667,120 | 4,501,104 |
| Deferred collaboration revenue | 754,198 | 1,050,124 | 1,091,267 | 641,158 |
| Total liabilities | 4,300,739 | 6,922,015 | 4,758,387 | 5,142,262 |
| Common stock, 0.0001 par value 200,000,000 shares authorized 23,457,183 and 20,934,456 shares issued and outstanding as of march 31, 2026 or december 31, 2025, respectively | 2,346 | 2,094 | 1,675 | 1,673 |
| Additional paid-in capital | 118,138,281 | 104,989,413 | 83,537,551 | 82,447,524 |
| Accumulated deficit | -69,170,267 | -61,963,277 | -56,254,735 | -54,138,904 |
| Total stockholders' equity | 48,970,360 | 43,028,230 | 27,284,491 | 28,310,293 |
| Total liabilities and stockholders' equity | 53,271,099 | 49,950,245 | 32,042,878 | 33,452,555 |
Coya Therapeutics, Inc. (COYA)
Coya Therapeutics, Inc. (COYA)